Overview

Adult Bipolar Mania

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Quintiles, Inc.
Treatments:
Lithium Carbonate
Quetiapine Fumarate